1) Antiplatelet Trialists' Collaboration:Collaborative overview of randomized trials of antiplatelet therapy-I:prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients. BMJ 308:81-106, 1994
2) Muir A, Cossar IA:Aspirin and ulcer. Br Med J 2:7-12, 1955
3) Douthwaite AH, Lond MD, Lintotto GAM:Gastroscopic observation of the effect of aspirin and certain other substances on the stomach. Lancet 232:1222-1224, 1938
4) 森本正好:「アスピリン」胃潰瘍の一例. 診断と治療 21:1044-1045, 1934
5) Huang JQ, Sridhar S, Hunt RH:Role of Helicobacter pylori and non-steroidal anti-inflammatory drugs in peptic ulcer disease:a meta-analysis. Lancet 359:14-22, 2002
6) Sakamoto C, Sugano K, Ota S et al:Case-control study on the association of upper gastrointestinal bleeding and nonsteroidal anti-inflammatory drugs in Japan. Eur J Clin Pharmacol 62:765-772, 2006
7) 塩川優一, 延永正, 斎藤輝信ほか:非ステロイド性抗炎症剤による上部消化管傷害に関する疫学調査. リウマチ 31:96-111, 1991
8) Rostom A, Dube C, Wells GA et al:Prevention of NSAID-induced gastroduodenal ulcers. Cochrane Database Syst Rev, 4:CDOO2296, 2002 (Review content assessed as up-to-date:11May 2009)
9) Yeomans ND, Lanas AI, Talley NJ et al:Prevalence and incidence of gastroduodenal ulcers during treatment with vascular protective doses of aspirin. Aliment Pharmacol Ther 22:795-801, 2005
10) Taha AS, McCloskey C, Prasad R et al:Famotidine for the prevention of peptic ulcers and oesophagitis in patients taking low-dose aspirin (FAMOUS):a phase III, randomised, double-blind, placebo-controlled trial. Lancet 374:119-125, 2009
11) Scheiman JM, Devereaux PJ, Herlitz J et al:Prevention of peptic ulcers with esomeprazole in patients at risk for ulcer development treated with low-dose acetylsalicylic acid:a randomised, controlled trial (OBERON). Heart, published online March 17, 2011
12) Sugano K, Matsumoto Y, Itabashi T et al:Lansoprazole for secondary prevention of gastric or duodenal ulcers associated with long-term low-dose aspirin therapy:results of a prospective, multicenter, double-blind, randomized, double-dummy, active-controlled trial. J Gastroenterol 46:724-735, 2011
13) Derry S, Loke YK:Risk of gastrointestinal haemorrhage with long term use of aspirin:meta-analysis. BMJ 321:1183-1187, 2000
14) Cryer B, Feldman M:Effects of very low dose daily, long-term aspirin therapy on gastric, duodenal, and rectal prostaglandin levels and on mucosal injury in healthy humans. Gastroenterology 117:17-25, 1999
15) MacDonald TM, Morant SV, Goldstein JL et al:Channelling bias and the incidence of gastrointestinal haemorrhage in users of meloxicam, coxibs, and older, non-specific non-steroidal anti-inflammatory drugs. Gut 52:1265-1270, 2003
16) Singh G, Fort JG, Goldstein JL et al:Celecoxib versus naproxen and diclofenac in osteoarthritis patients:SUCCESS-I Study Am J Med 119:255-266, 2006
17) Kelly JP, Kaufman DW, Jurgelon JM et al:Risk of aspirin-associated major upper-gastrointestinal bleeding with enteric-coated or buffered product. Lancet 348:1413-1416,1996
18) Petroski D:Endoscopic comparison of three aspirin preparations and placebo. Clin Ther 15:314-320, 1993
19) Wolfe MM, Lichtenstein DR, Singh G:Gastrointestinal toxicity of nonsteroidal antiinflammatory drugs. N Engl J Med 340:1888-1899, 1999
20) EBMに基づく胃潰瘍診療ガイドライン第2版, 胃潰瘍診療ガイドラインの適用と評価に関する研究班, じほう, 東京, 2007, pp. 101-110
21) Lanza FL, Chan FK, Quigley EM:Practice parameters committee of the American college of gastroenterology. Guidelines for prevention of NSAID-related ulcer complications. Am J Gastroenterol 104:728-738, 2009
22) Lanas A, Scheiman J:Low-dose aspirin and upper gastrointestinal damage:epidemiology, prevention and treatment. Curr Med Res Opin 23:163-173, 2007
23) Bhatt DL, Scheiman J, Abraham NS et al:ACCF/ACG/AHA 2008 expert consensus document on reducing the gastrointestinal risks of antiplatelet therapy and NSAID use. Am J Gastroenterol 103:2890-2907, 2008
24) Chan FK, Chung SC, Suen BY et al:Preventing recurrent upper gastrointestinal bleeding in patients with Helicobacter pylori infection who are taking low-dose aspirin or naproxen. N Engl J Med 344:967-973, 2001
25) Fletcher EH, Johnston DE, Fisher CR et al:Systematic review:Helicobacter Pylori and the risk of upper gastrointestinal bleeding risk in patients taking aspirin. Aliment Pharmacol Ther 32:831-839, 2010
26) Charlot M, Grove EL, Hansen PR et al:Proton pump inhibitor use and risk of adverse cardiovascular events in aspirin treated patients with first time myocardial infarction:nationwide propensity score matched study. BMJ 342:d2690, 2011